What SCICLONE PHARMACEUTICALS INC's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director | Oct 13 | Disposition to Issuer · D | −24,363 | $11.18 | −$272K | 0 |
| Chang Nancy T | Director | Oct 13 | Disposition to Issuer · D | −70,000 | $11.18 | −$783K | 0 |
| Chern Carey | General Counsel | Oct 13 | Disposition to Issuer · D | +20,708 | $11.18 | +$232K | 0 |
| Chern Carey | General Counsel | Oct 13 | Withheld — tax / exercise cost · F | −11,274 | $11.18 | −$126K | 20,708 |
| Chern Carey | General Counsel | Oct 13 | Exercise / conversion · M | +30,000 | — | — | 31,982 |
| Cheung Wilson Wai-Shun | CFO & Senior VP, Finance | Oct 13 | Disposition to Issuer · D | −144,158 | $11.18 | −$1.61M | 0 |
| Cheung Wilson Wai-Shun | CFO & Senior VP, Finance | Oct 13 | Grant / award · A | +75,000 | — | — | 144,158 |
| Cheung Wilson Wai-Shun | CFO & Senior VP, Finance | Oct 13 | Exercise / conversion · M | +52,000 | — | — | 69,158 |
| Xie Lan | VP Finance, China CFO | Oct 13 | Disposition to Issuer · D | −8,000 | $11.18 | −$89.4K | 0 |
| Xie Lan | VP Finance, China CFO | Oct 13 | Exercise / conversion · M | +8,000 | — | — | 8,000 |
| Blobel Friedhelm | President, CEO, Director | Oct 13 | Disposition to Issuer · D | −387,299 | $11.18 | −$4.33M | 0 |
| Blobel Friedhelm | President, CEO, Director | Oct 13 | Grant / award · A | +150,000 | — | — | 387,299 |
| Blobel Friedhelm | President, CEO, Director | Oct 13 | Exercise / conversion · M | +95,000 | — | — | 237,299 |
| Zhao Hong | CEO, China Operations | Oct 13 | Grant / award · A | +75,000 | — | — | 127,000 |
| Zhao Hong | CEO, China Operations | Oct 13 | Exercise / conversion · M | +52,000 | — | — | 52,000 |
| Low Raymond Anthony | VP, Finance & Controller | Oct 13 | Disposition to Issuer · D | −37,748 | $11.18 | −$422K | 0 |
| Low Raymond Anthony | VP, Finance & Controller | Oct 13 | Exercise / conversion · M | +11,250 | — | — | 37,748 |
| Saxe Jon S | Director | Oct 13 | Disposition to Issuer · D | −135,000 | $11.18 | −$1.51M | 0 |
| Zhao Hong | CEO, China Operations | Oct 13 | Disposition to Issuer · D | −127,000 | $11.18 | −$1.42M | 0 |
| Zhao Hong | CEO, China Operations | Aug 16 | Open-market sale · S | −30,000 | $11.00 | −$330K | 0 |
Loading...
